The Michigan Center for Thyroid Eye Disease and Orbital Surgery is part of Consultants in Ophthalmic and Facial Plastic Surgery, PC and consists of a team of surgeons and physician assistants who are dedicated to the treatment of this disfiguring and vision-threatening disease.
The TED team brings together a wealth of knowledge and experience with thyroid eye disease (TED), also known as thyroid orbitopathy or Graves orbitopathy. The team includes Dr. Robert Beaulieu and physician assistant Lindsay El-Awadi.
Dr. Robert Beaulieu
Dr. Beaulieu is a board-certified ophthalmologist and completed his residency in ophthalmology at the University of Texas Southwestern in Dallas, Texas, the largest and one of the busiest training programs in the country. Following residency, he completed a two-year fellowship in Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) through the Kresge Eye Institute and William Beaumont Hospital. Dr. Beaulieu has extensive experience in treating patients with TED using surgical and medical approaches.
Lindsay El-Awadi has spent 2 years partnering with professionals at the University of Michigan, providing medical and surgical support to the evaluation and treatment of patients with TED. As oculoplastic PAs, Lindsay has developed unique expertise in the care of patients with TED, including the management of eye irritation and dryness that often accompany the disease. Leaving the University of Michigan to join Consultants in Ophthalmic and Facial Plastic Surgery, Lindsay works closely with Dr. Beaulieu to provide coordinated care to patients with TED. With our surgeon and PA, there is always someone at the Michigan Center for TED who is available to evaluate patients.
The clinical team of the Michigan Center for TEDOS works closely with endocrinologists, endocrine surgeons and radiologists throughout the region and nationally to coordinate the care of patients with Thyroid Eye Disease. Through extensive and research-driven experience, we can provide patients with TED unmatched care: from supportive care for the symptoms of mild TED, such as eye irritation and tearing, to biological drug infusions for patients with progressive disease, to sophisticated customized surgical care for patients with more advanced and even vision-threatening disease. The goal of treatment is to minimize the risk of progressive disease, while restoring patients to looking, feeling and functioning as they did before.